[Object]It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis； arteriosclerosis such as those resulting from diabetes； dyslipidemia； hypercholesterolemia； lipid-related diseases； inflammatory diseases that are caused by inflammatory cytokines； skin diseases such as allergic skin diseases； diabetes； or Alzheimer's disease.[Solving Means]A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate:(wherein, each V and W independently show N or C—R7； each X and Y independently show CH2, C═O, SO2, etc； Z shows CH or N； each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.； R3 shows C1-8 alkyl group； R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group； R5 and R6 show a hydrogen atom, etc.； L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.； and n shows any integer of 0 to 2.)
